Healthcare Crisis: Beyond Austerity Measures

Stories of patients unable to access vital medications for conditions like diabetes and cancer, or facing postponed surgeries due to supply shortages, are becoming increasingly common in Mexico. While initial explanations pointed to austerity policies and administrative inefficiencies, a deeper investigation suggests a more troubling reality.

Unveiling Irregularities: The Cost of Corruption

A comprehensive review of official documents and data indicates that institutions like IMSS (Mexican Social Security Institute) and Birmex (state-owned pharmaceutical company) may have significantly overpaid for medications. These alleged overpayments, reaching as high as 800% above market value, reportedly benefited companies with ties to Rocío Nahle, the former Secretary of Energy and current Governor of Veracruz, and also entities linked to the Cuban government and newly established businesses.

From official information and the review of hundreds of documents, it was found that institutions such as IMSS and Birmex paid up to 800% more expensive each medicine to companies related to Rocío Nahle, former Secretary of Energy and today Governor of Veracruz, with the Government of Cuba and other companies created months before receiving the first contracts.

A Web of Acquisition Mechanisms: Opportunities for Abuse

The investigation highlights the existence of multiple, overlapping mechanisms for procuring medications under the López Obrador administration’s “republican austerity” policy. This complex system, intended to streamline spending, allegedly created fertile ground for irregular contracting practices that enriched a select few at the expense of public health. According to a 2024 report by the World Health Organization, inefficient procurement processes are a major contributor to inflated drug prices and limited access in many developing nations.

The Paradox of increased Spending: Where Did the Money Go?

The central question raised by this investigation is: how could the AMLO government increase spending on medicine purchases by 29% and still fail to provide adequate treatment to patients? This paradox suggests that the increased funds were not effectively translated into improved healthcare outcomes, perhaps due to corruption and mismanagement.

Featured Audio Investigation

Listen to the full investigation for an in-depth analysis of the alleged corruption and its impact on the Mexican healthcare system.